Sense Biodetection
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Sense Biodetection was a UK molecular diagnostics company headquartered in Cambridge (with operations in Milford, Massachusetts). It built Veros, an instrument-free rapid molecular test platform using proprietary amplification chemistries and disposable hardware — point-of-care diagnostics with the speed of an antigen test (about 15 minutes) but PCR-level accuracy (97.9%). Veros COVID-19 received its CE Mark in March 2022 with strong clinical performance in sensitivity and specificity, launching country by country across Europe and South America to enthusiastic distributor uptake. Investors included Cambridge Innovation Capital; the company raised about $81.5 million.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- CE Mark and launch
Sense receives the CE Mark in March 2022 for Veros COVID-19, its rapid instrument-free molecular test; the product launches country by country across Europe and South America with strong distributor demand.
- Acquired by Sherlock Biosciences
On February 1, 2023, US-based Sherlock Biosciences announces the acquisition of Sense Biodetection for undisclosed terms, pairing Sherlock's CRISPR, synthetic biology and AI technologies with Sense's instrument-free diagnostic hardware, rapid amplification chemistries and manufacturing capabilities to accelerate handheld consumer diagnostics.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.